Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Expression of Toll-like Receptor 9 Increases with Progression of Cervical Neoplasia in Tunisian Women - A Comparative Analysis of Condyloma, Cervical Intraepithelial Neoplasia and Invasive Carcinoma

  • Fehri, Emna (HPV Unit Research. Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases) ;
  • Ennaifer, Emna (HPV Unit Research. Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases) ;
  • Ardhaoui, Monia (HPV Unit Research. Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases) ;
  • Ouerhani, Kaouther (HPV Unit Research. Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases) ;
  • Laassili, Thalja (HPV Unit Research. Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases) ;
  • Rhouma, Rahima Bel Haj (HPV Unit Research. Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases) ;
  • Guizani, Ikram (HPV Unit Research. Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases) ;
  • Boubaker, Samir (Department of Human and Experimental Pathology, Pasteur Institute of Tunis)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Toll-like receptors (TLRs) are expressed in immune and tumor cells and recognize pathogen-associated molecular patterns. Cervical cancer (CC) is directly linked to a persistent infection with high risk human papillomaviruses (HR-HPVs) and could be associated with alteration of TLRs expression. TLR9 plays a key role in the recognition of DNA viruses and better understanding of this signaling pathway in CC could lead to the development of novel immunotherapeutic approaches. The present study was undertaken to determine the level of TLR9 expression in cervical neoplasias from Tunisian women with 53 formalin-fixed and paraffin-embedded specimens, including 22 samples of invasive cervical carcinoma (ICC), 18 of cervical intraepithelial neoplasia (CIN), 7 of condyloma and 6 normal cervical tissues as control cases. Quantification of TLR9 expression was based on scoring four degrees of extent and intensity of immunostaining in squamous epithelial cells. TLR9 expression gradually increased from CIN1 (80% weak intensity) to CIN2 (83.3% moderate), CIN3 (57.1% strong) and ICC (100% very strong). It was absent in normal cervical tissue and weak in 71.4% of condyloma. The mean scores of TLR9 expression were compared using the Kruskall-Wallis test and there was a statistical significance between normal tissue and condyloma as well as between condyloma, CINs and ICC. These results suggest that TLR9 may play a role in progression of cervical neoplasia in Tunisian patients and could represent a useful biomarker for malignant transformation of cervical squamous cells.

Keywords

References

  1. Akira S (2009). Pathogen recognition by innate immunity and its signaling. Proc Jpn Acad Ser B Phys Biol Sci, 85, 143-56. https://doi.org/10.2183/pjab.85.143
  2. Al Moustafa AE, Al-Awadhi R, Missaoui N, et al (2014). Human papillomaviruses-related cancers: Presence and prevention strategies in the Middle east and North African Regions. Hum Vaccin Immunother, 30, 10.
  3. Andersen JM, Al-Khairy D, Inqalls RR (2006). Innate immunity at mucosal surface. Role of Toll-like receptor 3 and Toll-like receptor 9 in cervical epithelial cell response to microbial pathogens. Biol Reprod, 74, 824-31. https://doi.org/10.1095/biolreprod.105.048629
  4. Bhattacharya D, Yusuf N (2012). Expression of toll-like receptors on breast tumors: taking a toll on tumor microenvironment. Int J breast Cancer, 2012, 716564.
  5. Boccardo E, Lepique AP, Villa LL (2010). The role of inflammation in HPV carcinogenesis. Carcinogenesis, 31, 1905-12. https://doi.org/10.1093/carcin/bgq176
  6. Bodelon C, Madeleine MM, Johnson LG, Du Q, Galloway DA, Malkki M, Petersdorf EW, Schwartz SM (2014). Genetic variation in the TLR and NF-кB pathways and cervical and vulvar cancer risk: a population-based case-control study. Int J Cancer, 134, 437-44. https://doi.org/10.1002/ijc.28364
  7. Chang LS, Leng CH, Yeh YC, et al (2014). Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumorassociated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy. Mol Cancer, 13, 60.
  8. Chen X, Wang S, Liu L, et al (2012). A Genetic Variant in the Promoter Region of Toll-Like Receptor 9 and Cervical Cancer Susceptibility. DNA Cell Biol, 31, 766-71. https://doi.org/10.1089/dna.2011.1427
  9. Cheng YX, Qi XY, Huang JL, et al (2012). Toll-like receptor 4 signaling promotes the immunosuppressive cytokine production of human cervical cancer. Eur J Gynaecol Oncol, 33, 291-4.
  10. Dai Q, Li XP, Chai L, Long HA, Yang ZH (2014). Polymorphisms of Toll-like receptor 9 are associated with nasopharyngeal carcinoma susceptibility. Tumour Biol, 35, 3247-53. https://doi.org/10.1007/s13277-013-1424-5
  11. Daud II, Scott ME, Ma Y, et al (2011). Association between tolllike receptor expression and human papillomavirus type 16 persistence. Int J Cancer, 128, 879-86. https://doi.org/10.1002/ijc.25400
  12. Decarlo CA, Rosa B, Jackson R, et al (2012). Toll-Like receptor transcriptome in the HPV-positive cervical cancer microenvironment. Clin Dev Immunol, 2012, 785825.
  13. Doan HQ, Bowen KA, Jackson LA, Evers BM (2009). Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res, 29, 2473-78.
  14. Domingos-Pereira S, Decrausaz L, Derre L, et al (2013). Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital tumor regression in mice. Mucosal Immunol, 6, 393-404. https://doi.org/10.1038/mi.2012.83
  15. El andaloussi A, Sonabend AM, Han Y, Lesniak MS (2006). Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia, 54, 526-35. https://doi.org/10.1002/glia.20401
  16. Geller MA, Cooley S, Argenta PA, et al (2010). Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother, 59, 1877-84. https://doi.org/10.1007/s00262-010-0914-1
  17. Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, et al (2011). Study of TLR3, TLR4 and TLR9 in prostate carcinoma and their association with biochemical recurrence. Cancer Immunol Immunother, 60, 217-26. https://doi.org/10.1007/s00262-010-0931-0
  18. Hanley SJ, Yoshioka E, Ito Y, et al (2014). An exploratory study of Japanese fathers' knowledge of and attitudes towards HPV and HPV vaccination: does marital status matter? Asian Pac J Cancer Prev, 15, 1837-43. https://doi.org/10.7314/APJCP.2014.15.4.1837
  19. Hasan UA, Bates E, Takeshita F, et al (2007). TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type16. J Immunol, 178, 3186-97. https://doi.org/10.4049/jimmunol.178.5.3186
  20. Hasan UA, Zannetti C, Parroche P, et al (2013). The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med, 210, 1369-87 https://doi.org/10.1084/jem.20122394
  21. Hasimu A, Ge L, Li QZ, Zhang RP, Guo X (2011). Expressions of Toll-like receptors 3, 4, 7 and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women. Chin J Cancer, 30, 344-50. https://doi.org/10.5732/cjc.010.10456
  22. Hirsch I, Caux C, Hasan U, Bendriss-Vermare N, Olive D (2010). Impaired Toll-like receptor 7 and 9 signaling : from chronic viral infections to cancer. Trends Immunol, 31, 391-7. https://doi.org/10.1016/j.it.2010.07.004
  23. Karim R, Meyers C. Backendorf C, et al (2011). Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One, 6, 17848. https://doi.org/10.1371/journal.pone.0017848
  24. Kim WY, Lee JW, Choi JJ, et al (2008). Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer, 18, 300-5. https://doi.org/10.1111/j.1525-1438.2007.01008.x
  25. Krug A, French A.R, Barchet W, et al (2004). TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity, 21, 107-19 https://doi.org/10.1016/j.immuni.2004.06.007
  26. Lai ZZ, Ni-Zhang, Pan XL, Song L (2013). Toll-like receptor 9 (TLR9) gene polymorphisms associated with increased susceptibility of human papillomavirus-16 infection in patients with cervical cancer. J Int Med Res, 41, 1027-36. https://doi.org/10.1177/0300060513483398
  27. Lee JW, Choi JJ, Seos ES, et al (2007). Increased Toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog, 46, 941-47. https://doi.org/10.1002/mc.20325
  28. Li J, Kang LN, Qiao YL (2011). Review of the cervical cancer disease burden in mainland China. Asian Pac J Cancer Prev, 12, 1149-53.
  29. Liu L, Li YH, Niu YB, et al (2010). An apple oligogalactan prevents against inflammation and carcinogenesis by targeting LPS/TLR4/NF-kB pathway in a mouse model of colitis-associated colon cancer. Carcinogenesis, 31, 1822-32. https://doi.org/10.1093/carcin/bgq070
  30. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki (2003). A tolllikereceptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med, 198, 513-20. https://doi.org/10.1084/jem.20030162
  31. Mason KA, Hunter NR (2012). CpG plus radiotherapy: a review of preclinical works leading to clinical trial. Front Oncol, 2, 1-6.
  32. Mai CW, Kang YB, Pichika MR (2013). Should a Toll-like receptor 4 (TLR-4) agonist antagonist be designed to treat cancer ? TLR-4 : its expression and effects in the most common cancers. Onco targets Ther, 6, 1573-87.
  33. Moreno-Eutimio MA, Altamirano GA, Vargas-Hernandez VM (2013). Expression of toll-like receptor 9 in cervical intraepithelial neoplasia from Mexican women. J Cytol Histol, 4, 4.
  34. Mvundura M, Tsu V (2014). Estimating the costs of cervical screening in high-burden Sub-Saharian African countries. Int J Gynaecol Obstet, 126, 151-5 https://doi.org/10.1016/j.ijgo.2014.02.012
  35. Ochi A, Graffeo CS, Zambrinis CP, et al (2012). Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest, 122, 4118-29. https://doi.org/10.1172/JCI63606
  36. Ohlschlager P, Spies E, Alvarez G, Quetting M, Groettrup M (2011). The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer, 128, 473-81. https://doi.org/10.1002/ijc.25344
  37. Oliveira LB, Louvanto K, Ramanakumar AV, et al (2013). Cohort Study. Polymorphism in the promoter region of the Toll-like receptor 9 gene and cervical human papillomavirus infection. J Gen Virol, 94, 1858-64. https://doi.org/10.1099/vir.0.052811-0
  38. Othman N, Othman NH (2014). Detection of human papillomavirus DNA in routine cervical scraping samples: use for a national cervical cancer screening program in a developing nation. Asian Pac J Cancer Prev, 15, 2245-9. https://doi.org/10.7314/APJCP.2014.15.5.2245
  39. Pandey S, Mittal B, Srivastava M, et al (2011). Evaluation of Toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms in cervical cancer susceptibility. Mol Biol Rep, 38, 4715-21. https://doi.org/10.1007/s11033-010-0607-z
  40. Roszak A, Lianeri M, Sowinska A, Jagodzinski PP (2012). Involvement of Toll-like Receptor 9 polymorphism in cervical cancer development. Mol Biol Rep, 39, 8425-30. https://doi.org/10.1007/s11033-012-1695-8
  41. Sajadian A, Tabarraei A, Soleimanjahi H, et al (2014). Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine. Arch Virol.
  42. Schmausser B, Andrulis M, Endrich S, Muller-Hermelink HK, Eck M (2005). Toll Like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol, 295, 179-85. https://doi.org/10.1016/j.ijmm.2005.02.009
  43. Schmidt C (2006). Immune system's Toll-like receptors have good opportunity for cancer treatment. J Natl Cancer Inst, 98, 574-5. https://doi.org/10.1093/jnci/djj198
  44. Sheyhidin I, Nabi G, Hasim A, et al (2011). Overexpression of TLR3, TLR4, TLR7 and TLR9 in oesophageal squamous cell carcinoma. World J Gastroenterol, 17, 3745-51. https://doi.org/10.3748/wjg.v17.i32.3745
  45. Spaner DE, Masellis A (2007). Toll like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia, 21, 53-60. https://doi.org/10.1038/sj.leu.2404456
  46. Wagner H (2012). Innate immunity's path to the Nobel Prize 2011 and beyond. Eur J Immunol, 42, 1089-92. https://doi.org/10.1002/eji.201242404
  47. Wang C, Cao S, Yang Y, et al (2010). TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer, 10, 415. https://doi.org/10.1186/1471-2407-10-415
  48. Wang JL, Yang YZ, Dong WW, et al (2013). Application of human papillomavirus in screening for cervical cancer and precancerous lesions. Asian Pac J Cancer Prev, 14, 2979-82. https://doi.org/10.7314/APJCP.2013.14.5.2979
  49. Wang YY, Li L, Wei S, et al (2013). Human papillomavirus (HPV) infection in women participating in cervical cancer screening from 2006 to 2010 in Shenzhen City, South China. Asian Pac J Cancer Prev, 14, 7483-87. https://doi.org/10.7314/APJCP.2013.14.12.7483
  50. Werner J, Decarlo CA, Escott N, Zehbe I, Ulanova M (2012). Expression of integrins and Toll-like receptors in cervical cancer: effect of infectious agents. Innate Immun, 18, 55-69. https://doi.org/10.1177/1753425910392934
  51. Weng Y, Wang Y, Shi Y, et al (2011). TLR9 expression and its role in chemosensitivity to DDP in human cervical cancer cells in vitro. Med Sci, 31, 550-4.
  52. Yang H, Zhou H, Feng P, et al (2010). Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res, 29, 92. https://doi.org/10.1186/1756-9966-29-92
  53. Yu L, Wang L, Li M, et al (2010). Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol Immunother, 59, 1021-8. https://doi.org/10.1007/s00262-010-0825-1
  54. Yu L, Wang L, Chen S. (2013). Dual character of Toll-like receptor signalling: pro-tumorigenic effects and anti-tumor functions. Bio Bio Acta, 1835, 144-54.
  55. Zhou Q, Zhu K, Cheng H (2013). Toll-like receptors in human papillomavirus infection. Arch Immunol Immunother Exp, 61, 203-15. https://doi.org/10.1007/s00005-013-0220-7
  56. Zolini GP, Lima GK, Lucinda N et al (2014). Defense against HSV-1 in a murine model is mediated by iNOS and orchestrated by the activation of TLR2 and TLR9 in trigeminal ganglia. J Neuroinflammation, 30, 11-20.
  57. Zur Hausen H (2009). Papillomavirus is the causation of human cancers- a brief historical account. Virology, 384, 260-5. https://doi.org/10.1016/j.virol.2008.11.046

Cited by

  1. TLR9 gene polymorphism −1486T/C (rs187084) is associated with uterine cervical neoplasm in Mexican female population vol.143, pp.12, 2017, https://doi.org/10.1007/s00432-017-2495-2
  2. Role of TLR9 in Oncogenic Virus-Produced Cancer vol.30, pp.2, 2017, https://doi.org/10.1089/vim.2016.0103
  3. The Relationship of the TLR9 and TLR2 Genetic Polymorphisms with Cervical Cancer Risk: a Meta-Analysis of Case-Control Studies pp.1532-2807, 2018, https://doi.org/10.1007/s12253-018-0465-x
  4. The Associations between Toll-Like Receptor 9 Gene Polymorphisms and Cervical Cancer Susceptibility vol.2018, pp.1466-1861, 2018, https://doi.org/10.1155/2018/9127146
  5. Therapeutic potential of toll‐like receptors in treatment of gynecological cancers pp.1521-6551, 2019, https://doi.org/10.1002/iub.2011